The dimerization of EGFR was demonstrated to require palmitoylation, induced by tyrosine kinase inhibitors (i.e., AEE788, gefitinib, and erlotinib) in a series of cancer cell lines including A549, MDA-MB-231, PC3, and DU145 [161]. The gene discussed is EGFR; the disease is cancer.